Cyclo Therapeutics, Inc. Expected to Post Q1 2024 Earnings of ($0.20) Per Share (NASDAQ:CYTH)

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Cyclo Therapeutics in a report issued on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Cyclo Therapeutics’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.47) EPS and FY2027 earnings at ($0.38) EPS.

Separately, Ascendiant Capital Markets began coverage on shares of Cyclo Therapeutics in a research note on Monday, April 22nd. They issued a “buy” rating and a $2.60 price objective for the company.

Cyclo Therapeutics Stock Performance

Shares of NASDAQ CYTH opened at $1.51 on Friday. Cyclo Therapeutics has a one year low of $0.89 and a one year high of $2.57. The firm has a market capitalization of $43.37 million, a P/E ratio of -1.15 and a beta of -0.18. The company’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.47.

Cyclo Therapeutics (NASDAQ:CYTH) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $0.31 million for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%.

Institutional Trading of Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund VI Management LLC acquired a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics makes up about 1.4% of Founders Fund VI Management LLC’s holdings, making the stock its 2nd largest holding. Founders Fund VI Management LLC owned about 0.48% of Cyclo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.